📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: SynCardia

1.1 - Company Overview

SynCardia Logo

SynCardia

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of total artificial heart technology, including the SynCardia temporary Total Artificial Heart used as a bridge to heart transplantation for patients with end-stage biventricular heart failure. Offers 70cc and 50cc biventricular replacement devices, the latter for patients of smaller stature, and is developing a Next Generation Total Artificial Heart.

Products and services

  • 50cc SynCardia Total Artificial Heart: Smaller-scale Total Artificial Heart engineered to bridge patients of smaller stature, including women and adolescents, to heart transplantation for end-stage heart failure
  • 70cc SynCardia Total Artificial Heart: Temporary biventricular replacement device built to bridge patients with end-stage biventricular heart failure to heart transplantation until a matching donor heart becomes available
  • Next Generation Total Artificial Heart: Upcoming design engineered to improve the current Total Artificial Heart technology for patients with end-stage heart failure

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to SynCardia

Mezzion Pharma Logo

Mezzion Pharma

HQ: United States Website
  • Description: Provider of pharmaceuticals developing and discovering medicines, including JURVIGO (udenafil), a medication to improve physiology and exercise capacity in patients aged 12+ with Fontan circulation. Supports clinical programs: FUEL-2 phase 3 trial evaluating udenafil in adolescents 12–18, FALD study on long-term liver effects, and FUEL OLE study on long-term safety.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Mezzion Pharma company profile →
Vdyne Logo

Vdyne

HQ: United States Website
  • Description: Provider of proprietary transcatheter valve technology to treat tricuspid regurgitation via a unique side-delivery method, enabling treatment for a broader patient population; developing tricuspid replacement valve and repair technology.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Vdyne company profile →
Huyabio Logo

Huyabio

HQ: United States Website
  • Description: Provider of novel biopharmaceutical product opportunities, including HBI-8000, an oral class I selective HDAC inhibitor for cancers; HBI-3000, a multi-ion channel blocker for atrial fibrillation; HBI-2376, an SHP2 inhibitor for solid tumors; HBI-ONC, an epigenetic inhibitor for MDS/AML; and HBI-3800, a small molecule to regenerate cardiac muscle damaged by ischemia.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Huyabio company profile →
BG Medicine Logo

BG Medicine

HQ: United States Website
  • Description: Provider of biomarker-based diagnostic tests for the cardiovascular sectors.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full BG Medicine company profile →
Cortex E&P Logo

Cortex E&P

HQ: United States Website
  • Description: Provider of an integrated suite of technologies for assessing and treating atrial fibrillation (AFib) with precision, simplicity, and speed.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Cortex E&P company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for SynCardia

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to SynCardia

2.2 - Growth funds investing in similar companies to SynCardia

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for SynCardia

4.2 - Public trading comparable groups for SynCardia

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to SynCardia

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About SynCardia

What does SynCardia do?

SynCardia is a provider of total artificial heart technology, including the SynCardia temporary Total Artificial Heart used as a bridge to heart transplantation for patients with end-stage biventricular heart failure. Offers 70cc and 50cc biventricular replacement devices, the latter for patients of smaller stature, and is developing a Next Generation Total Artificial Heart.

Who are SynCardia's competitors?

SynCardia's competitors and similar companies include Mezzion Pharma, Vdyne, Huyabio, BG Medicine, and Cortex E&P.

Where is SynCardia headquartered?

SynCardia is headquartered in United States.

How many employees does SynCardia have?

SynCardia has 1,000 employees 🔒.

When was SynCardia founded?

SynCardia was founded in 2010 🔒.

What sector and industry vertical is SynCardia in?

SynCardia is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for SynCardia

Who are the top strategic acquirers in SynCardia's sector and industry

Top strategic M&A buyers and acquirers in SynCardia's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for SynCardia?

Top strategic M&A buyers groups and sectors for SynCardia include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in SynCardia's sector and industry vertical

Which are the top PE firms investing in SynCardia's sector and industry vertical?

Top PE firms investing in SynCardia's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in SynCardia's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in SynCardia's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in SynCardia's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to SynCardia include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in SynCardia's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for SynCardia?

The key public trading comparables and valuation benchmarks for SynCardia include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for SynCardia for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for SynCardia with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in SynCardia's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for SynCardia with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in SynCardia's' sector and industry vertical?

Access recent funding rounds and capital raises in SynCardia's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for SynCardia